AbbVie vs Eli Lilly: Strategic Comparison
Direct Answer
Eli Lilly is now larger by revenue, profit and market value. Lilly reported $65.2 billion of revenue for 2025, up 44.7%, against AbbVie's $61.2 billion, up 8.6%. Lilly's net income was $20.6 billion against AbbVie's $4.2 billion, and on September 29, 2026 Lilly was worth about $1.06 trillion, more than twice AbbVie's $465.3 billion.
AbbVie and Eli Lilly represent two corporate pharmaceutical powerhouses that have achieved dramatic commercial transformations through distinct therapeutic focal points in immunology, oncology, and metabolic endocrinology. AbbVie Inc. recorded $54.3 billion in worldwide revenue in 2023, successfully managing the patent cliff of Humira—historically the world's highest-grossing pharmaceutical product—by rapidly scaling its next-generation immunology blockbusters Skyrizi and Rinvoq alongside its Allergan aesthetics franchise (Botox). Eli Lilly and Company recorded $34.1 billion in revenue in 2023 and experienced unprecedented market capitalization expansion exceeding $700 billion, driven by the global commercial explosion of its dual GIP and GLP-1 receptor agonist tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). The two companies reflect divergent operating profiles: AbbVie delivers massive operating cash flow from commercialized specialty portfolios, while Lilly trades at premium growth multiples driven by the massive expansion of the global anti-obesity pharmaceutical market.
Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.
Key Differences at a Glance
| Field | AbbVie Inc. | Eli Lilly and Company |
|---|---|---|
| Latest annual revenue | $61.2B (FY2025) | $65.2B (FY2025) |
| Founded | 2013 | 1876 |
| Employees | 57,000 | 50,000 |
| Market Cap | $465.8B | $1.06T |
| Headquarters | United States | United States |
| Revenue / Employee | $1.07M / employee | $1.30M / employee |
| Valuation Multiple | 7.6x P/S | 16.3x P/S |
Strategic Positioning
Business model and competitive context from the cited profiles
AbbVie Inc. Strategic Vector
FY2025 Revenue BaselineAbbVie's corporate roadmap focuses on expanding Skyrizi and Rinvoq into additional autoimmune indications while aggressively replenishing its oncology and neuroscience pipelines through targeted mergers and acquisitions. Led by Chief Executive Officer Robert Michael, AbbVie completed the acquisitions of ImmunoGen for ten billion dollars (adding Elahere, a pioneering antibody-drug conjugate for folate receptor alpha-positive platinum-resistant ovarian cancer) and Cerevel Therapeutics for nearly nine billion dollars (adding emraclidine for schizophrenia and tavapadon for Parkinson's disease). In neuroscience, AbbVie continues to expand Botox Therapeutic and oral CGRP antagonists (Qulipta, Ubrelvy) for migraine management. By pairing cash flow from aesthetics and immunology with next-generation antibody-drug conjugates (ADCs), AbbVie has established a sustainable post-Humira growth trajectory.
Eli Lilly and Company Strategic Vector
FY2025 Revenue BaselineEli Lilly's corporate strategy focuses on expanding manufacturing capacity to meet soaring global demand for incretin therapeutics while advancing a diversified next-generation biopharmaceutical pipeline. Under Chief Executive Officer David Ricks, Lilly committed more than eighteen billion dollars to construct and expand state-of-the-art sterile injectable manufacturing campuses in Indiana, North Carolina, Ireland, and Germany to alleviate supply bottlenecks for Mounjaro and Zepbound. Concurrently, the company is pioneering oral, small-molecule GLP-1 receptor agonists (orforglipron) to provide convenient pill alternatives to weekly injections, alongside triple-hormone agonists (retatrutide) targeting GIP, GLP-1, and glucagon receptors for profound metabolic intervention. In neuroscience, the regulatory approval of Kisunla (donanemab) positions Lilly at the forefront of amyloid-clearing Alzheimer's therapies, creating another long-duration therapeutic franchise.
Quick Stats Comparison
| Metric | AbbVie Inc. | Eli Lilly and Company |
|---|---|---|
| Revenue | $61.2B (FY2025) | $65.2B (FY2025) |
| Founded | 2013 | 1876 |
| Headquarters | North Chicago, Illinois | Indianapolis, Indiana |
| Market Cap | $465.8B | $1.06T |
| Employees | 57,000 | 50,000 |
| Revenue / Employee | $1.07M / employee | $1.30M / employee |
| Valuation Multiple | 7.6x P/S | 16.3x P/S |
AbbVie Revenue vs Eli Lilly Revenue — Year by Year
| Year | AbbVie Inc. | Eli Lilly and Company | Higher reported revenue |
|---|---|---|---|
| 2025 | $61.2B | $65.2B | Eli Lilly and Company (approx. USD) |
| 2024 | $56.3B | $45.0B | AbbVie Inc. (approx. USD) |
| 2023 | $54.3B | $34.1B | AbbVie Inc. (approx. USD) |
| 2022 | $58.1B | $28.5B | AbbVie Inc. (approx. USD) |
| 2021 | $56.2B | $28.3B | AbbVie Inc. (approx. USD) |
Business Model Breakdown
Overview: AbbVie Inc. vs Eli Lilly and Company
This in-depth comparison examines AbbVie Inc. and Eli Lilly and Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Eli Lilly and Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Eli Lilly and Company is widest.
On the headline numbers, annual revenue is $61.2B (FY2025) for AbbVie Inc. and $65.2B (FY2025) for Eli Lilly and Company, while their respective market capitalizations stand at $465.8B and $1.06T. Both AbbVie Inc. and Eli Lilly and Company are headquartered in United States. Their local markets and applicable rules may still differ.
AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics. The company is headquartered in North Chicago, Illinois.
Eli Lilly and Company: Eli Lilly is a 150-year-old Indianapolis pharmaceutical company that has become the world's largest drugmaker by market value. For most of its history it was best known for insulin and Prozac. Since 2022, tirzepatide, a dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, has transformed its scale, taking revenue from $28.5 billion in 2022 to $65.2 billion in 2025 and a guided $85-87 billion in 2026. The company is headquartered in Indianapolis, Indiana.
Business Models: How AbbVie Inc. and Eli Lilly and Company Make Money
AbbVie Inc. and Eli Lilly and Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Eli Lilly and Company.
AbbVie Inc. business model: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie built its initial commercial empire around Humira (adalimumab)—historically the world's best-selling biologic medicine. Today, AbbVie's business model is anchored by its next-generation immunology franchise: Skyrizi (risankizumab for plaque psoriasis, psoriatic arthritis, and Crohn's disease) and Rinvoq (upadacitinib for rheumatoid arthritis, ulcerative colitis, and atopic dermatitis). Through its landmark sixty-three-billion-dollar acquisition of Allergan, AbbVie operates a lucrative commercial aesthetics and therapeutic franchise led by Botox (Botox Cosmetic and Botox Therapeutic for migraine, spasticity) and the Juvederm dermal filler portfolio, alongside specialized oncology therapeutics like Venclexta and Imbruvica.
Eli Lilly and Company business model: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. The company's business model is powered by targeted biologic therapies and synthetic peptide chemistry, generating revenue through patent-protected prescription drug sales to pharmaceutical wholesalers, hospital systems, and pharmacy benefit managers. Eli Lilly's revenue flywheel is led by its dual GIP/GLP-1 receptor agonist franchise—tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Beyond metabolic health, the company derives substantial recurring cash flows from oncology (Verzenio for HR+/HER2- breast cancer), immunology (Taltz, Omvoh), and neuroscience (Kisunla/donanemab for early symptomatic Alzheimer's disease). Revenue is reinvested at industry-leading rates into clinical trials, automated fill-finish manufacturing plants, and novel drug delivery platforms.
Competitive Advantage: AbbVie Inc. vs Eli Lilly and Company
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Eli Lilly and Company.
AbbVie Inc. competitive advantage: AbbVie's durable competitive moat is built upon its world-class commercial execution in immunology, unmatched patent estate design, and the high-margin cash flow engine of the Allergan aesthetics portfolio. When facing the loss of exclusivity for Humira in the United States, AbbVie executed one of the most successful commercial pipeline replacements in biopharma history: developing Skyrizi and Rinvoq with superior clinical efficacy, securing favorable formulary placement with pharmacy benefit managers, and guiding them to combined annual revenues that surpass Humira's peak. In aesthetics, Botox operates with high consumer brand equity and medical practitioner loyalty; because cosmetic neurotoxin injections require physician skill and patient trust, Botox commands extraordinary pricing power and consumer cash-pay insulation from insurance reimbursement cuts.
Eli Lilly and Company competitive advantage: Eli Lilly's formidable economic moat is founded on its multi-decade dominance in peptide synthesis, patent-protected intellectual property, and extensive global sterile manufacturing infrastructure. The development of tirzepatide established a first-in-class multi-receptor incretin platform that demonstrated superior glycemic control and weight reduction compared to single-hormone alternatives, granting Eli Lilly formidable pricing power and formulary tier positioning across private and public health insurance programs. Developing complex biologic therapies requires specialized high-speed parenterals, automated aseptic syringe filling lines, and rigorous peptide purification facilities that represent multi-billion-dollar barriers to entry. Lilly's patent portfolio creates statutory commercial exclusivity lasting through the next decade, while its clinical development velocity consistently brings breakthrough molecular entities from early discovery to regulatory approval ahead of historical pharmaceutical timelines.
Growth Strategy: Where AbbVie Inc. and Eli Lilly and Company Are Headed
Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Eli Lilly and Company each plan to expand from here.
AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.
Eli Lilly and Company growth strategy: Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3. Lilly continues to build U.S. and European manufacturing capacity and uses acquisitions to add pipeline assets.
Financial Picture: AbbVie Inc. vs Eli Lilly and Company
A closer look at the financial trajectory of AbbVie Inc. and Eli Lilly and Company rounds out the comparison.
AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets. AbbVie is a dominant biopharmaceutical company, sustaining a massive market valuation often exceeding $250 billion, heavily driven by its blockbuster immunology and aesthetics portfolios.
Eli Lilly and Company: Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.
Company-Specific SWOT Notes
AbbVie Inc.
Skyrizi generated $17.562 billion and Rinvoq generated $8.304 billion in FY2025 global net revenue, or $25.866 billion combined, after U.S. Humira biosimilar entry.
AbbVie is no longer only an immunology company.
Humira's decline shows the core weakness of the pharmaceutical model: even notable blockbusters eventually lose exclusivity.
Even after diversification, AbbVie's earnings power is tied heavily to Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Humira.
Cerevel adds neuroscience pipeline depth, while ImmunoGen adds Elahere and antibody-drug conjugate expertise.
U.S. drug-pricing pressure remains a major threat.
Eli Lilly and Company
Lilly's tirzepatide franchise represents one of the most commercially successful pharmaceutical launches in history, with combined Mounjaro and Zepbound revenues of $36.5 billion in fiscal year 2025 and significant additional indication expansion in developmen
With more than 50 active molecules in clinical development and $13.3 billion invested in R&D in fiscal year 2025, Lilly's pipeline represents one of the most productive in the pharmaceutical industry.
Despite a multi-billion-dollar manufacturing expansion program, Lilly's production capacity for tirzepatide and other injectable biologics has lagged the notable demand generated by commercial launches, resulting in drug shortages that have frustrated patients
Tirzepatide, sold as Mounjaro and Zepbound, produced about 56% of Lilly's 2025 revenue and roughly 65% of Q2 2026 revenue.
The FDA approved Foundayo (orforglipron) on April 1, 2026, making it the first small-molecule GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions.
The Inflation Reduction Act's Medicare drug price negotiation program, which allows the Centers for Medicare and Medicaid Services to directly negotiate prices for high-expenditure drugs, represents a structural threat to Lilly's revenue model in the United St
Factual Scorecard
| Category | Result | Why |
|---|---|---|
| Same-period Revenue Scale | Eli Lilly and Company | $61.2B (FY2025) versus $65.2B (FY2025); the higher figure is identified after approximate USD conversion. |
| Founded Earlier | Eli Lilly and Company | AbbVie Inc. was founded in 2013; Eli Lilly and Company was founded in 1876. |
Comparison Takeaway: AbbVie vs Eli Lilly
Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.
Frequently Asked Questions: AbbVie vs Eli Lilly
How did AbbVie replace Humira revenue after biosimilar competition started in 2023?
AbbVie successfully offset Humira's revenue erosion through its two next-generation immunology blockbusters: Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor). In 2023, Skyrizi generated $7.7 billion and Rinvoq generated $3.97 billion, with AbbVie forecasting combined peak sales exceeding $27 billion by 2027.
Why did Eli Lilly's market capitalization surpass $700 billion in 2024?
Eli Lilly's market valuation surged due to the extraordinary commercial demand and clinical efficacy of tirzepatide (Mounjaro and Zepbound). Tirzepatide demonstrated superior weight loss (up to 20-25%) compared to competing single GLP-1 treatments, positioning Lilly at the forefront of a global obesity market projected to reach $100 billion by 2030.
How do AbbVie and Eli Lilly compare in dividend yields?
AbbVie is a member of the S&P 500 Dividend Aristocrats index, historically maintaining a dividend yield between 3.5% and 4.5% backed by strong operating cash flows. Eli Lilly offers a much lower dividend yield (under 1.0%), as the market prices Lilly as a high-growth biotechnology compounder reinvesting heavily in manufacturing capacity and clinical R&D.
What are Eli Lilly's primary growth drivers beyond obesity and diabetes?
Beyond tirzepatide, Lilly's growth drivers include Verzenio (CDK4/6 inhibitor for breast cancer), Taltz (IL-17A inhibitor for psoriasis), Jaypirca (BTK inhibitor for lymphoma), and Kisunla (donanemab for early symptomatic Alzheimer's disease).
What are the commercial prospects of oral weight-loss drugs compared to injectable tirzepatide?
Eli Lilly is developing orforglipron, an investigational oral non-peptide GLP-1 receptor agonist designed for daily oral ingestion without food or water restrictions. If Phase 3 trials confirm efficacy comparable to injectable therapies, orforglipron could dramatically expand global patient access, bypass cold-chain syringe manufacturing constraints, and reinforce Lilly's leadership across international cardiometabolic markets.
Which company was founded first, AbbVie Inc. or Eli Lilly and Company?
Eli Lilly and Company was founded in 1876; AbbVie Inc. was founded in 2013.
What revenue did AbbVie Inc. and Eli Lilly and Company report?
AbbVie Inc. had $61.2B (FY2025), while Eli Lilly and Company had $65.2B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.
How do AbbVie Inc. and Eli Lilly and Company make money?
AbbVie Inc.: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Eli Lilly and Company: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience.
Which is better, AbbVie Inc. or Eli Lilly and Company?
There is no evidence-based single winner. Compare AbbVie Inc. and Eli Lilly and Company on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.
Sources & References
- SEC EDGAR: AbbVie Inc. filings search (10-K, 8-K)
- AbbVie Inc. Corporate Website
- AbbVie Inc. 2025 revenue figure: SEC EDGAR company facts for AbbVie Inc.
- sec.gov
- news.abbvie.com
- investors.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- prnewswire.com
- fda.gov
- cms.gov
- stockanalysis.com
- SEC EDGAR: Eli Lilly and Company filings search (10-K, 8-K)
- Eli Lilly and Company Corporate Website
- Eli Lilly and Company 2025 revenue figure: sec.gov
- data.sec.gov
- investor.lilly.com
- en.wikipedia.org
- finance.yahoo.com
- stockanalysis.com
- investor.lilly.com
- cnbc.com
- investor.lilly.com
- investor.lilly.com
Quick Answer
Eli Lilly is now larger by revenue, profit and market value. Lilly reported $65.2 billion of revenue for 2025, up 44.7%, against AbbVie's $61.2 billion, up 8.6%. Lilly's net income was $20.6 billion against AbbVie's $4.2 billion, and on September 29, 2026 Lilly was worth about $1.06 trillion, more than twice AbbVie's $465.3 billion.
Verdict
AbbVie offers exceptional cash-flow generation, an attractive dividend payout profile, and a de-risked post-Humira growth trajectory powered by market-leading immunology and neuroscience assets. Eli Lilly provides unrivaled top-line growth velocity and market leadership in the multi-hundred-billion-dollar global obesity and diabetes therapeutic space, commanding a premium valuation based on tirzepatide's transformative clinical efficacy.
Cite This Page
Automatically generated citations for researchers.
CorpDigest. (2026). AbbVie Inc. vs Eli Lilly and Company Comparison. from https://corpdigest.com/compare/abbvie-vs-eli-lilly
CorpDigest. "AbbVie Inc. vs Eli Lilly and Company Comparison." CorpDigest, 2026, https://corpdigest.com/compare/abbvie-vs-eli-lilly.
CorpDigest. "AbbVie Inc. vs Eli Lilly and Company Comparison." CorpDigest. 2026. https://corpdigest.com/compare/abbvie-vs-eli-lilly.